MVM Partners LLC Sells 13,631,579 Shares of OptiNose, Inc. (NASDAQ:OPTN)

MVM Partners LLC trimmed its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 973,684 shares of the company's stock after selling 13,631,579 shares during the quarter. OptiNose makes up approximately 5.1% of MVM Partners LLC's investment portfolio, making the stock its 3rd largest position. MVM Partners LLC owned about 9.68% of OptiNose worth $6,363,000 at the end of the most recent quarter.

Separately, State Street Corp boosted its position in shares of OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company's stock valued at $229,000 after acquiring an additional 42,500 shares during the last quarter. Institutional investors own 85.60% of the company's stock.

Insider Buying and Selling

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now owns 126,931 shares in the company, valued at approximately $671,464.99. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 8,213 shares of company stock valued at $43,643 in the last ninety days. Company insiders own 2.30% of the company's stock.

OptiNose Stock Up 0.1 %

NASDAQ OPTN traded up $0.01 on Friday, reaching $9.40. The stock had a trading volume of 21,187 shares, compared to its average volume of 60,954. OptiNose, Inc. has a 12-month low of $4.82 and a 12-month high of $20.03. The stock has a fifty day moving average price of $8.01 and a two-hundred day moving average price of $7.58. The firm has a market capitalization of $95.19 million, a price-to-earnings ratio of -2.24 and a beta of -0.88.

OptiNose (NASDAQ:OPTN - Get Free Report) last posted its earnings results on Wednesday, March 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.67. The firm had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million. Sell-side analysts forecast that OptiNose, Inc. will post -3.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on OPTN shares. Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and reduced their target price for the stock from $17.00 to $9.00 in a research note on Thursday, March 20th. Piper Sandler reissued a "neutral" rating and set a $9.00 target price (down previously from $15.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, HC Wainwright reiterated a "neutral" rating and set a $9.00 price target (down from $18.00) on shares of OptiNose in a report on Friday, March 21st.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.